Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL809786 | 0.98 | CCR5 (0.31) | CCR5 | |
| Hydrochloric Acid SCHEMBL1691842 | 0.97 | CCR5 (0.33) | CCR5 | |
| Bromide SCHEMBL14992842 | 0.94 | CCR5 (0.34) | CCR5 | |
| SCHEMBL2420361 | 0.94 | CCR5 (0.33) | CCR5 | |
| Bromide SCHEMBL14993400 | 0.93 | — | — | |
| SCHEMBL809578 | 0.92 | CCR5 (0.35) | CCR5 | |
| SCHEMBL809788 | 0.92 | CCR5 (0.35) | CCR5 | |
| SCHEMBL809728 | 0.92 | CCR5 (0.35) | CCR5 | |
| SCHEMBL810033 | 0.92 | CCR5 (0.35) | CCR5 | |
| SCHEMBL810016 | 0.92 | CCR5 (0.35) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2785726-B1 | ESTER-FUNCTIONAL SILANES AND THE PREPARATION AND USE THEREOF; AND USE OF IMINIUM COMPOUNDS AS PHASE TRANSFER CATALYSTS | DOW SILICONES CORP (US) | 2018-08-01 | — | — | EP | disclosed |
| US-9518072-B2 | Ester-functional silanes and the preparation and use thereof; and use of iminium compounds as phase transfer catalysts | DOW CORNING CORPORATION (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150126676-A1 | Ester-Functional Silanes And The Preparation And Use Thereof; And Use Of Iminium Compounds As Phase Transfer Catalysts | DOW SILICONES CORPORATION | 2015-05-07 | — | — | US | disclosed |
| EP-2785726-A2 | ESTER-FUNCTIONAL SILANES AND THE PREPARATION AND USE THEREOF; AND USE OF IMINIUM COMPOUNDS AS PHASE TRANSFER CATALYSTS | Dow Corning Corporation (US) | 2014-10-08 | — | — | EP | disclosed |
| WO-2013081820-A2 | ESTER-FUNCTIONAL SILANES AND THE PREPARATION AND USE THEREOF;AND USE OF IMINIUM COMPOUNDS AS PHASE TRANSFER CATALYSTS | DOW CORNING CORPORATION (US) | 2013-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126676-A1 | Ester-Functional Silanes And The Preparation And Use Thereof; And Use Of Iminium Compounds As Phase Transfer Catalysts | ICMT, INTS9, HDHD5 | CCR5 1514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.